文献速递冠心病心律失常

EXCEL试验:左主干病变PCI或CABG术后新发心房颤动

New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

EXCEL试验纳入1905例左主干病变且SYNTAX评分低/中危患者,随机接受PCI或CABG。1,812例入院时无房颤者中,CABG组新发房颤发生率18.0%(161/893),PCI组仅0.1%(1/919),P<0.0001。CABG术后新发房颤独立预测3年卒中(aHR 4.19)、死亡(aHR 3.02)及死亡/心梗/卒中复合终点(aHR 2.13)。

要点

  • CABG术后新发房颤常见(18.0%),PCI术后极罕见(0.1%)。
  • CABG术后新发房颤独立增加3年卒中、死亡及复合终点风险。
  • 新发房颤者住院更长、出院抗凝更多,30天TIMI出血更高(14.2% vs 5.5%)。

核心结论

  • 左主干病变血运重建后,新发房颤在CABG术后常见而在PCI术后极罕见。
  • CABG术后新发房颤与后续死亡和卒中强烈相关。

研究设计与样本

  • EXCEL试验为随机对照试验,纳入1,905例左主干病变且SYNTAX评分低或中危患者,随机接受依维莫司洗脱支架PCI或CABG。
  • 分析基于1,812例入院时无房颤患者,按血运重建后初始住院期间是否发生新发房颤分组。

主要发现

  • 新发房颤在血运重建后平均2.7±2.5天发生,共162例(8.9%)。
  • CABG组新发房颤161/893(18.0%),PCI组1/919(0.1%),p<0.0001。
  • CABG患者中新发房颤的独立预测因素包括年龄较大、体重指数较高和左心室射血分数降低。
  • 新发房颤者住院时间显著更长、出院时抗凝治疗更多,30天TIMI大或小出血发生率14.2% vs 5.5%(p<0.0001)。
  • CABG术后新发房颤独立预测3年卒中(6.6% vs 2.4%;aHR 4.19;95%CI 1.74-10.11;p=0.001)、死亡(11.4% vs 4.3%;aHR 3.02;95%CI 1.60-5.70;p=0.0006)及死亡/心梗/卒中复合终点(22.6% vs 12.8%;aHR 2.13;95%CI 1.39-3.25;p=0.0004)。

临床怎么用

  • CABG术后应警惕新发房颤,因其与3年卒中、死亡及复合终点风险显著升高相关。
  • 对新发房颤患者需关注抗凝治疗与出血风险的平衡。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited information on the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD). OBJECTIVES: This study sought to determine the incidence of NOAF following PCI and CABG for LMCAD and its effect on 3-year cardiovascular outcomes. METHODS: In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with LMCAD and low or intermediate SYNTAX scores were randomized to PCI with everolimus-eluting stents versus CABG. Outcomes were analyzed according to the development of NOAF during the initial hospitalization following revascularization. RESULTS: Among 1,812 patients without atrial fibrillation on presentation, NOAF developed at a mean of 2.7 ± 2.5 days after revascularization in 162 patients (8.9%), including 161 of 893 (18.0%) CABG-treated patients and 1 of 919 (0.1%) PCI-treated patients (p < 0.0001). Older age, greater body mass index, and reduced left ventricular ejection fraction were independent predictors of NOAF in patients undergoing CABG. Patients with versus without NOAF had a significantly longer duration of hospitalization, were more likely to be discharged on anticoagulant therapy, and had an increased 30-day rate of Thrombolysis In Myocardial Infarction major or minor bleeding (14.2% vs. 5.5%; p < 0.0001). By multivariable analysis, NOAF after CABG was an independent predictor of 3-year stroke (6.6% vs. 2.4%; adjusted hazard ratio [HR]: 4.19; 95% confidence interval [CI]: 1.74 to 10.11; p = 0.001), death (11.4% vs. 4.3%; adjusted HR: 3.02; 95% CI: 1.60 to 5.70; p = 0.0006), and the primary composite endpoint of death, MI, or stroke (22.6% vs. 12.8%; adjusted HR: 2.13; 95% CI: 1.39 to 3.25; p = 0.0004). CONCLUSIONS: In patients with LMCAD undergoing revascularization in the EXCEL trial, NOAF was common after CABG but extremely rare after PCI. The development of NOAF was strongly associated with subsequent death and stroke in CABG-treated patients. Further studies are warranted to determine whether prophylactic strategies to prevent or treat atrial fibrillation may improve prognosis in patients with LMCAD who are undergoing CABG. (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kosmidou I, Chen S, Kappetein AP, et al. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. J Am Coll Cardiol. 2018. PMID: 29447735. doi:10.1016/j.jacc.2017.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。